Actinium Pharmaceuticals awarded a non-qualified stock option for 3,000 shares at $1.40 each to a newly hired non-executive employee as an inducement to join the company. The options vest over four years, with 28% vesting after one year and the remainder monthly over the next three years, contingent on continued employment. This grant is outside the company's existing stock plan and aims to attract talent to support its development of targeted radiotherapies for cancer. Actinium is advancing multiple cancer treatment candidates, including therapies for solid tumors and blood cancers, with ongoing clinical trials and collaborations with the National Cancer Institute.
Actinium Pharmaceuticals' inducement grant to a new employee is presented here with Pluang's health sector market data for context. Among 150 priced health-sector US stocks on Pluang as of Oct 31, 2026 03:11 WIB, 51 rose while 99 fell. Notably, Inovio Pharmaceuticals Inc (INO) dropped 19.66% to USD 0.62 with 94% buy orders, contrasting with Illumina, Inc. (ILMN) at USD 236.36 down 18.51% but with 100% buy orders, and American Well Corp (AMWL) at USD 12.71 down 15.15%, also with 100% buy orders. Typical hold times ranged from 43 to 84 days across these stocks.
3E Network Technology Group Limited received a notice from Nasdaq that its Class A shares will be delisted due to the share price falling below $1.00 for 30 consecutive business days. The company is not eligible for a compliance period because of a r...
Philips has introduced the HyperVue Integrated System in the U.S., a fixed, single-room setup combining DeepOCT+NIRS imaging with X1-FFR physiology assessment for coronary interventions. This system is designed to streamline cath lab workflows by kee...
Atlas Copco Group completed Expansion Week in the US, unveiling three major manufacturing expansions in New York and South Carolina. The new facilities will increase production of oil-free compressors, dry vacuum pumps, and gas and process equipment,...
Mohawk Industries reported Q3 2026 net sales of $2.8 billion, up about 1%, driven by price increases offsetting lower volumes amid weak demand. Adjusted EPS rose 2% to $2.72, supported by productivity and pricing strategies. The company generated $39...
Anthropic is expected to receive a high "junk" credit rating from agencies following its IPO, according to the Financial Times. Blackstone, a major investor in Anthropic's $63 billion chip financing deal, now predicts a double B rating, the top tier ...
